Description

Psma-617 is a high-purity, small-molecule radiopharmaceutical precursor designed for targeted radioligand therapy. This compound is critical for the precise delivery of therapeutic radioisotopes to prostate-specific membrane antigen (PSMA)-expressing cells. It is primarily utilized by pharmaceutical manufacturers, radiopharmaceutical research facilities, and clinical trial organizations developing next-generation cancer therapeutics for prostate cancer and other PSMA-positive malignancies.

Application

• Radiopharmaceutical Synthesis: As a key precursor for labeling with therapeutic radionuclides such as Lutetium-177 (177Lu) or Actinium-225 (225Ac) for targeted radioligand therapy (TLT).
• Preclinical & Clinical Research: For the development and evaluation of novel PSMA-targeted therapeutic agents in oncology research.
• Active Pharmaceutical Ingredient (API): Serves as the non-radioactive component in the manufacturing of finished drug products like 177Lu-PSMA-617.
• Theragnostic Development: Used in conjunction with diagnostic PSMA-targeting agents to enable a theragnostic approach in prostate cancer management.
• Reference Standard: Acts as a critical analytical standard for quality control and regulatory compliance in radiopharmaceutical production.

Basic Information

Product Name	Psma-617
CAS No.	1702967-37-0
Molecular Formula	C46H68N10O14
Molecular Weight	961.1 g/mol
Synonyms	PSMA-617; PSMA617; DOTAGA-(I-y)fk(Sub-KuE); (R)-N-[[(1-Carboxy-4-[[4-[[(S)-1-carboxy-3-(4-iodophenyl)propyl]amino]-4-oxobutanoyl]amino]butyl)amino]-4-oxobutyl]-N6-(carboxymethyl)-N6-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl)-L-lysyl-L-tyrosyl-4-fluoro-L-phenylalanyl-L-norleucinamide; DOTAGA-PSMA; DOTAGA-PSMA-617; Pluvicto precursor
EINECS	Contact for details

Quality Control

Our Psma-617 is manufactured under strict quality management systems. Each batch undergoes comprehensive analytical testing, including HPLC for purity, MS for identity confirmation, and stringent controls for residual solvents and heavy metals. Certificates of Analysis (COA) are provided, detailing compliance with in-house specifications developed for pharmaceutical applications. We support development and commercial projects requiring materials suitable for use under cGMP guidelines.

Storage

Preserve in a tightly closed container, protected from light. Store at -20°C or below in a dedicated freezer. For long-term storage under an inert atmosphere, such as argon or nitrogen, is recommended to maintain stability. Allow the sealed vial to equilibrate to room temperature before opening to minimize moisture condensation.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (HPLC/MS)	Conforms to reference standard
Purity (HPLC)	≥ 95.0%
Single Largest Impurity (HPLC)	≤ 2.0%
Water Content (KF)	≤ 5.0%
Heavy Metals	≤ 20 ppm
Residual Solvents (GC)	Meets ICH Q3C guidelines

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.